Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections
Authors:
- Richard GaleRGRichard Gale
- Rachel L W HansonRHRachel L W Hanson
- Paul TaylorPTPaul Taylor
- UK EMR Database Users GroupUGUK EMR Database Users Group
- 22 September 2020
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 105 (11) , 1571-1576
Abstract
Background/Aims To assess the effectiveness, burden and safety of two categories of treatment for central retinal vein occlusion (CRVO): intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) and dexamethasone (Ozurdex). Methods A retrospective analysis of Medisoft electronic medical record (EMR) data from 27 National Health Service sites in the UK identified 4626 treatment-naive patients with a single mode of treatment for macular oedema secondary to CRVO. Statistics describing the overall CRVO patient cohort and individual patient subpopulations stratified by treatment type were generated. Mean age at baseline, gender, ethnicity, social deprivation and visual acuity (VA) follow-up was reported. Absolute and change in VA using ETDRS are used to describe treatment effectiveness, the number of injections and visits used to describe treatment burden and endophthalmitis rates as a marker of treatment safety. Results Mean VA was 47.9 and 45.3 EDTRS letters in the anti-VEGF and Ozurdex groups, respectively. This changed to 57.9/53.7 at 12 months, 58.3/46.9 at 18 months and 59.4/51.0 at 36 months. Mean number of injections were 5.6/1.6 at 12 months, 6.0/1.7 at 18 months and 7.0/1.8 at 36 months. Endophthalmitis rates were 0.003% (n=4) for the anti-VEGF group and 0.09% (n=1) for the Ozurdex group. Conclusions VA improvements were greater and more sustained with anti-VEGF treatment. Lower starting acuity resulted in bigger gains in both groups, while higher starting acuity resulted in higher VA at 36 months. Although treatment burden was greater with anti-VEGF, Ozurdex was associated with higher rates of endophthalmitis.Keywords
This publication has 20 references indexed in Scilit:
- The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab InjectionsOphthalmology, 2014
- Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with RanibizumabOphthalmology, 2014
- Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein OcclusionOphthalmology, 2014
- Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS StudyAmerican Journal of Ophthalmology, 2013
- Ranibizumab for Macular Edema Due to Retinal Vein OcclusionsOphthalmology, 2012
- Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein OcclusionOphthalmology, 2011
- Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III StudyOphthalmology, 2011
- NOVEL METHOD FOR ANALYZING SNELLEN VISUAL ACUITY MEASUREMENTSRetina, 2010
- Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein OcclusionOphthalmology, 2010
- Photocoagulation for Diabetic Macular EdemaArchives of Ophthalmology (1950), 1985